Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients (DTIC-melvacc)

This study has been completed.
Sponsor:
Collaborators:
Regina Elena Cancer Institute
University of Rome Tor Vergata
Information provided by:
Istituto Superiore di Sanità
ClinicalTrials.gov Identifier:
NCT00559026
First received: November 15, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 2006
  Estimated Primary Completion Date: No date given